LATEST NEWS

Terumo BCT Evolves Brand to Terumo Blood and Cell Technologies

Mallinckrodt and Terumo BCT Announce Positive Recommendations in Australia for Public Funding of UVADEX^® (methoxsalen) for ECP Administration with the THERAKOS^® CELLEX^® Photopheresis System for Treatment of Cutaneous T-Cell Lymphoma (CTCL) in Adults

A Look Inside Terumo BCT's Impact on Convalescent Plasma for COVID-19

First COVID-19 Patient Receives Therapy Targeting Cytokine Storm Under FDA EUA

Terumo BCT’s Mirasol reduces the virus causing COVID-19 below the limit of detection in plasma and platelets

Terumo Donates USD 2.4 Million in Cash and Products to Support COVID-19 Pandemic Relief Efforts Worldwide

Terumo BCT’s Mirasol Shows Efficacy Against Virus Causing COVID-19 in Plasma and Platelets

Terumo BCT and Marker Therapeutics received the first device FDA Emergency Use Authorization (EUA) to treat acute respiratory failure in COVID-19 patients

Terumo BCT Message: COVID-19

Terumo BCT’s Mirasol^® Pathogen Reduction Technology (PRT) System Demonstrates Reduced Risk of Transfusion Transmission of MERS-CoV, a strain of Coronavirus